<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01789762</url>
  </required_header>
  <id_info>
    <org_study_id>2012-P001</org_study_id>
    <nct_id>NCT01789762</nct_id>
  </id_info>
  <brief_title>Evaluation of the Efficacy of Platelets Treated With Pathogen Reduction Process</brief_title>
  <acronym>EFFIPAP</acronym>
  <official_title>Evaluation of the Efficacy of Platelets Treated With Pathogen Reduction Process</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Etablissement Français du Sang</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University Hospital, Grenoble</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Etablissement Français du Sang</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is a multicentre, double-blind, randomized therapeutic trial.&#xD;
&#xD;
      The primary objective of this study is to evaluate non-inferiority with regard to prevention&#xD;
      and control of haemorrhage:&#xD;
&#xD;
        -  of platelet concentrates treated by pathogen reduction(Intercept amotosalen and UVA&#xD;
           procedure)&#xD;
&#xD;
        -  compared with the usual platelet concentrates (in additive solution intersol), reference&#xD;
           arm, and&#xD;
&#xD;
        -  compared with platelet concentrates re-suspended in autologous plasma (historic arm)&#xD;
           These three products are available and authorised by ANSM (formerly AFSSAPS).&#xD;
&#xD;
      The secondary objectives is to evaluate the transfusion needs, transfusion outcomes and&#xD;
      safety and the decreased frequency of grade 2 or higher side effects related to transfusion&#xD;
      allergy to platelets.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      There is an unresolved difficulty in the evaluation of haemorrhagic symptoms in&#xD;
      thrombocytopenia due to the very nature of the scale, which is the international standard at&#xD;
      this time (WHO scale). This scale is based on the level of blood loss and is applicable to&#xD;
      any haemostasis disorder. We will keep it as the standard but have decided to be particularly&#xD;
      rigorous in the data collection and will perform daily haemorrhagic assessment.&#xD;
&#xD;
      Several sequences of missing data can be imputed for one patient. Each sequence of missing&#xD;
      data will be replaced if and only if the number of consecutive days missing does not exceed&#xD;
      15%* of the total length of the patient's stay. If one sequence of missing data is longer&#xD;
      than the 15%, no replacement will be done for the patient. (Example: If the total stay is 30&#xD;
      days, the maximal length of a missing data sequence accepted is 4 days). The following&#xD;
      strategies will be used to replace missing data:&#xD;
&#xD;
      • The first observation is missing: Next observation carried backwards (NOCB) assigns the&#xD;
      next known score after the missing value to the missing one.&#xD;
&#xD;
      • The last observation is missing: Last observation carried forward (LOCF) assigns the last&#xD;
      known score before the missing value to the missing one. (Suppose that the situation is&#xD;
      stable whilst the patient is leaving the hospital.)&#xD;
&#xD;
      • Sequence of one or several missing data with non-missing data before and after the&#xD;
      sequence: Last and Next1 assigns the average of the person's last known and next known&#xD;
      observation to the missing value. The score is rounded down to the nearest whole number if&#xD;
      needed. (Ex mean (1+2) =1)&#xD;
&#xD;
      * 15% rounded up to nearest whole number.&#xD;
&#xD;
      1 : Engels, J.M. 2003. Imputation of Missing Longitudinal Data : a Comparison of Methods.&#xD;
      Journal of Clinical Epidemiology 56 (2003) 968-976&#xD;
&#xD;
      Following a quality analysis of EFFIPAP study's recruitment, it was decided by the sponsor to&#xD;
      increase the number of patients. Approximatively thirty additional patients will be included&#xD;
      in order to replace non analyzable patients for the following reasons : wrongly included,&#xD;
      non-transfused patients, consent withdrawal. Those 30 additional patients will allow us to&#xD;
      reach our initial target of 810 analyzable patients in order to respond to the main objective&#xD;
      of the study&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>May 2013</start_date>
  <completion_date type="Actual">January 2016</completion_date>
  <primary_completion_date type="Actual">January 2016</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of grade 2 or higher (WHO) haemorrhagic episodes</measure>
    <time_frame>During 1 month</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Frequency incidence of haemorrhagic episodes (grade 1 and higher)</measure>
    <time_frame>During 1 month</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of serious grade 3-4 haemorrhagic episodes</measure>
    <time_frame>During 1 month</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of minor grade 1 haemorrhagic episodes</measure>
    <time_frame>During 1 month</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Transfusion outcome in platelets (CCI) at 24 hours</measure>
    <time_frame>During 1 month</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of transfusions of platelet concentrates and red blood cells</measure>
    <time_frame>During 1 month</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Transfusion intervals</measure>
    <time_frame>During 1 month</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety (transfusion side effects) grade 2 or higher</measure>
    <time_frame>During 1 month</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Occurrence of anti-platelet antibodies (Anti-HLA, anti-HPA)</measure>
    <time_frame>During 1 month</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Occurrence of platelet transfusions refractiveness</measure>
    <time_frame>During 1 month</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Validation of a new haemorrhagic evaluation: EFS scale</measure>
    <time_frame>During 1 month</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Variation in hematocrit and hemoglobin levels</measure>
    <time_frame>During 1 month</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">842</enrollment>
  <condition>Aplasia With Expected Thrombocytopenia</condition>
  <arm_group>
    <arm_group_label>Historical control arm</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients transfused with platelet concentrates re-suspended in autologous plasma</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control arm</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients transfused with platelets prepared in additive solution</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Experimental arm</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients transfused with platelets treated by pathogen reduction process</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Autologous plasma</intervention_name>
    <description>Transfusions of platelet concentrates re-suspended in autologous plasma</description>
    <arm_group_label>Historical control arm</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Additive solution</intervention_name>
    <description>Transfusions of platelets prepared in additive solution (Intersol)</description>
    <arm_group_label>Control arm</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Pathogen reduction process</intervention_name>
    <description>Patients transfused with platelets treated by pathogen reduction process</description>
    <arm_group_label>Experimental arm</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients aged 18 years or older&#xD;
&#xD;
          -  Patient hospitalised for bone marrow aplasia, with expected stay of over 10 days and&#xD;
             in principle requiring platelet transfusion support (at least twice).&#xD;
&#xD;
          -  Signed informed consent&#xD;
&#xD;
          -  Patients with DIC can be included; they will undergo a separate analysis.&#xD;
&#xD;
          -  A negative pregnancy test is necessary before inclusion in all women of childbearing&#xD;
             age&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patient included in this trial previously during a prior aplasia episode.&#xD;
&#xD;
          -  Patient requiring curative anticoagulant treatment at the time of inclusion (vitamin K&#xD;
             antagonists, heparin (LMWH and NFH), anti-IIa and Xa at curative doses for treatment&#xD;
             or prophylaxis of arterial or venous thromboembolic disease (TED) or as part of the&#xD;
             treatment for cardiac valvulopathy and complications of atrial fibrillation).&#xD;
&#xD;
          -  Thrombocytopenia due to increased destruction&#xD;
&#xD;
          -  Patient requires washed platelet concentrates (i.e., with residual plasma less than&#xD;
             that remaining during the addition of an additive solution) due to previous&#xD;
             intolerance to platelets (cf IgA deficiency, history of major allergic reaction)&#xD;
&#xD;
          -  Patient requiring products &quot;CMV negative &quot; (previously included in a protocol&#xD;
             transfusion CMV negative)&#xD;
&#xD;
          -  Patients with platelet transfusion refractoriness during a previous period of&#xD;
             cytopenia, including patient with platelet refractoriness related to an anti-HLA&#xD;
             alloimmunization (thus, patient already known as requiring compatible platelets HLA)&#xD;
&#xD;
          -  Patient who requires compatible HLA platelets due to a refractory state relative to&#xD;
             anti-HLA alloimmunization&#xD;
&#xD;
          -  Patient presenting a platelet transfusion refractoriness at the time of previous&#xD;
             aplasia.&#xD;
&#xD;
          -  Protected adults and persons deprived of liberty&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>CHU de Besancon</name>
      <address>
        <city>Besancon</city>
        <zip>25030</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU de Brest</name>
      <address>
        <city>Brest</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU de Clermont Ferrand</name>
      <address>
        <city>Clermont Ferrand</city>
        <zip>63003</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU Henri Mondor - APHP</name>
      <address>
        <city>Creteil</city>
        <zip>94000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU de Dijon</name>
      <address>
        <city>Dijon</city>
        <zip>21000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU de Grenoble</name>
      <address>
        <city>Grenoble</city>
        <zip>38700</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hopital Huriez - CHRU Lille</name>
      <address>
        <city>Lille</city>
        <zip>59037</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institut Paoli Calmette</name>
      <address>
        <city>Marseille</city>
        <zip>13273</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hopital Saint Antoine</name>
      <address>
        <city>Paris</city>
        <zip>75012</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospices Civils de Lyon - Lyon Sud</name>
      <address>
        <city>Pierre Benite</city>
        <zip>69495</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU de Rennes</name>
      <address>
        <city>Rennes</city>
        <zip>35033</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institut de Cancérologie de la Loire</name>
      <address>
        <city>St Priest en Jarez</city>
        <zip>42271</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>August 2016</verification_date>
  <study_first_submitted>February 8, 2013</study_first_submitted>
  <study_first_submitted_qc>February 8, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 12, 2013</study_first_posted>
  <last_update_submitted>April 26, 2019</last_update_submitted>
  <last_update_submitted_qc>April 26, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">April 29, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Platelet transfusions</keyword>
  <keyword>Pathogen reduction</keyword>
  <keyword>Haemorrhagic episodes</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Thrombocytopenia</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

